GlassScriptPhysician profile
Jesse A Stoff
NPI 1477637312
$9,116.15
in general payments reported to CMS, 2019-2025
36 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $484 · 2021: $1,965 · 2022: $1,413 · 2023: $1,257 · 2024: $1,730 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,297 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.28 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,628.69 | 2019-2025 | Creon, Viberzi, Linzess |
| Nestle Healthcare Nutrition INC. | $1,146.19 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $654.17 | 2019-2024 | Opdivo |
| Pfizer INC. | $597.57 | 2019-2024 | |
| Qol Medical, LLC | $586.59 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $509.58 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $414.92 | 2019-2025 | Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $377.68 | 2021-2022 | |
| Grifols USA, LLC | $238.50 | 2022-2025 | Xembify |
| Vivus LLC | $223.15 | 2021-2025 | Qsymia, Pancreaze |
| Csl Behring | $186.28 | 2023-2025 | Hizentra |
| Menarini Silicon Biosystems, INC. | $161.92 | 2023-2024 | Cellsearch |
| Lundbeck LLC | $150.19 | 2021-2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $130.76 | 2019-2024 | Alunbrig |
| Mirati Therapeutics, INC. | $129.75 | 2023-2024 | Krazati |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $101.97 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $100.79 | 2023-2025 | NP Thyroid 60 |
| Allergan, INC. | $90.84 | 2019-2020 | |
| Stemline Therapeutics INC. | $77.84 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $56.38 | 2022-2023 | Monoferric |
| Azurity Pharmaceuticals, INC. | $54.06 | 2023 | Adthyza |
| Exact Sciences Corporation | $51.21 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.52 | 2021-2022 | |
| Tempus Ai, INC | $46.91 | 2025 | Xt Cdx |
| Lilly USA, LLC | $46.15 | 2024 | Jaypirca, Verzenio |
| Genentech USA, INC. | $42.52 | 2019-2021 | |
| Pharmaand Gmbh | $42.49 | 2024-2025 | Rubraca |
| Eisai INC. | $38.82 | 2021 | |
| Emd Serono, INC. | $37.66 | 2019-2021 | |
| Blueprint Medicines Corporation | $28.27 | 2021 | |
| Tolmar, INC. | $23.53 | 2025 | Rubraca |
| Janssen Biotech, INC. | $21.93 | 2025 | Erleada |
| Puma Biotechnology, INC. | $19.01 | 2019 | |
| Shire North American Group INC | $18.57 | 2019 | |
| Clarus Therapeutics INC. | $18.00 | 2021 | |
| Hikma Pharmaceuticals USA | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Stoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.